Abbott received a warning letter from the Food and Drug Administration related to its FreeStyle Libre continuous glucose monitors. The warning letter, dated Jan. 23 and posted to the FDA’s website on ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) received an FDA warning ...

A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...

Theranica, a neuromodulation therapeutics company advancing clinically validated, drug-free treatments for idiopathic pain conditions and setting a new standard of care in migraine with REN-based ...

Study Confirms Safety of Using Theranica’s Nerivio REN Wearable for Treatment of Migraine Simultaneously with Contemporary Continuous Glucose Monitoring (CGM) Devices Published in the Journal of ...

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes ...

Sequel Med Tech and (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration.

Feb. 4 (UPI) --Officials for Abbott Diabetes Care have recalled some of the company's FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitor sensors for people with diabetes. The Food ...

The US Food and Drug Administration has escalated the recall of specific Abbott FreeStyle Libre 3 and 3 Plus continuous glucose monitors to Class I, the highest level of urgency. The recall, which ...

Abbott Diabetes Care is recalling certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to falsely low glucose readings.

The FDA has updated some information about the December recall of certain Abbott FreeStyle Libre 3 and 3 Plus glucose sensors. In December 2025, FDA posted an early alert that Abbott Diabetes Care was ...